• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Regeneron Pharmaceuticals (REGN)

Common Shares
Sell: $800.00|Buy: $811.00|Change: 14.07 (-1.72%)

Open 

$819.09

Previous close 

$819.09

Trade high 

$819.09

Volume 

527,740

Year high 

$859.34

Year low 

$575.93

Dividend yield 

0.46%

Market capitalisation 

$82.88 bn

P/E ratio 

19.92

ISIN 

US75886F1075

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Share price

Dividends

PreviousLatest
Record date20/05/202618/08/2026
Ex-dividend date20/05/202618/08/2026
Payment date04/06/202631/08/2026
Amount$0.94$0.94

Performance 23/10/2026

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

Total return (%)
Regeneron Pharmaceuticals- 1.72
More...

Company profile

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Sector 

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.